Logo

AZN logo AstraZeneca PLC (AZN) price target and intrinsic value estimate

AZN's fair price estimate is $58.8.

This valuation is based on a fair P/E of 14.7 and EPS estimates of $4.01, and calculated using the pevaluation method.

AZN is currently trading at $64.49 (10% overvalued).

0

Is AZN overvalued or undervalued?

AZN is overvalued by 10% using the pevaluation method.

0
0
Current price $64.5
Fair price $58.8

Define your own market model and access personalized fair price estimates today!

AZN logo
AstraZeneca PLC
AZN
64.49 (-0.03%) 0.02
Fair price estimates:
Low ($3.01 EPS)
$44.1
Average ($4.01 EPS)
$58.8
High ($5.01 EPS)
$73.5
My holdings
My holdings:
Shares:
Cost basis:
Health Care
Pharmaceuticals
Market cap:$ 199.79(B)
Enterprise value:$ 227.04(B)
Div. yield:2.30%
P/E:30.98
P/FCF:21.20
P/B:5.06
DescriptionNotes
AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company’s marketed products include Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Farxiga Brilinta Lokelma Roxadustat Andexxa Crestor Seloken Onglyza Bydureon Fasenra Breztri Symbicort Saphnelo Tezspire Pulmicort Bevespi and Daliresp for cardiovascular renal metabolism and oncology. Its marketed products also comprise Vaxzevria Beyfortus Synagis FluMist Soliris Ultomiris Strensiq Koselugo and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom rest of Europe the Americas Asia Africa and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.
PEvaluation
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: None/narrow
None/narrowMediumWideVery wide
Fair P/E
Margin of safety
EPS estimates
Currentprice:64.5Buy price49.1Fair price58.8
Analyst recommendations
S. Sell:
0
Sell:
2
Hold:
3
Buy:
10
S. Buy:
4
TTM Financials
Income
RevenueGrossNet
Balance sheet
Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Cash flow
CFOCFICFF
Growth estimates
Revenue Upgrade
EPS10.3%

Historical financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade
YearlyQuarterly
Income
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
RevenueNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AOperating IncomeInterest ExpenseInterest IncomePre-tax incomeIncome tax
Cash flow
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
FCFCFONet IncomeD&AStock-based Comp.CFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Shares outstanding
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Shares (Basic)Shares (Diluted)
Per share data
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
EPS (Basic)EPS (Diluted)FCF/ShareDividend/ShareBook value/Share
Ratios
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
P/EP/FCFP/BP/SEV/EarningsEV/FCFDebt/EquityPayout ratio
Margins
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin
Returns
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
ROICROAROCEROE
Market Cap.
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Market Cap.